US 11851497
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11851497 (CD137 antibodies and tumor antigen-targeting antibodies and uses thereof) held by Compass Therapeutics LLC expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61P, A61P35/00